ASCELIA AN ONCOLOGY-DEDICATED DRUG DEVELOPMENT COMPANY ACE 31.30 SEK -1.88% 2021-12-02 18:00:00 EN SV ABOUT US THERAPEUTIC AREAS PIPELINE PARTNERING IR & MEDIA GOVERNANCE CAREER CONTACT ADVANCING ORPHAN ONCOLOGY TO IMPROVE THE LIFE OF PEOPLE LIVING WITH CANCER BY OFFERING BETTER TREATMENT OPTIONS OUR STORY Our Vision Our vision is to be a leader in identifying, developing and commercializing novel drugs that address unmet needs of people with rare cancer conditions. Learn more about us: Ascelia Pharma company presentation Dec 2021 Q3-2021 investor conference call READ MORE EXHIBITION Meet us at RSNA in Chicago NOVEMBER 28 – DECEMBER 2 Ascelia Pharma will be at the world’s largest radiology conference RSNA in Chicago. On 1st December, Dr. Kohkan Shamsi will present the abstract for Orviglance comparison study to gadolinium. Press release with the study results RSNA 2021 presentation SSGI12-2 Kohkan Shamsi READ MORE VIEW ALL EVENTS UPCOMING EVENTS 2022-02-10 Full year report 2021 (January-December 2021) Report will be released at 8.00am CET and conference call at 10.00am CET 2022-02-10 Full year report 2021 (January-December 2021) Report will be released at 8.00am CET and conference call at 10.00am CET 2022-05-05 Annual General Meeting 2022 Annual General Meeting 2022 View all events LATEST NEWS 2021-12-01 Results from Orviglance comparison study to gadolinium presented at RSNA 2021 Ascelia Pharma AB (publ) (ticker: ACE) today presented results at the world’s largest radiology conference, RSNA, in Chicago, Illinois from the study in which the investigational contrast agent Orviglance® was compared against a gadolinium-based contrast agent. 2021-12-01 Nomination Committee appointed for AGM 2022 in Ascelia Pharma AB Ascelia Pharma AB (publ) (ticker: ACE) today announces that the Nomination Committee in preparation for the Annual General Meeting (AGM) on 5 May 2022 has been appointed 2021-12-01 Quarterly Report Q3 2021: Oncoral – entering clinical collaboration Ascelia Pharma AB (publ) (ticker: ACE) today published its quarterly financial report for Q3 2021 (July – September 2021), which is now available on the company’s website: https://www.ascelia.com/ir-media/reports-presentations/ View all PRESENTATIONS 2021-11-11 Redeye Life Science Day 2021 Ascelia Pharma CEO Magnus Corfitzen presents at Redeye Life Science Day. 2021-11-04 Q3 2021 Financial Presentation The Executive Managment in Ascelia Pharma presents a business update and the quarterly results 2021-10-06 HC Andersen/Nordea Small & Mid Cap Seminar CEO Magnus Corfitzen presents at the Danish HC Andersen/Nordea Small & Mid cap seminar (presentation in Danish) View all INVESTOR Shortcut to our latest Financial Reports IR & Media Key downloads PEOPLE Meet our CEO Magnus Corfitzen Listen to Ascelia Pharma’s CEO Magnus Corfitzen and the vision and plans for the company Learn more About us Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance® (former working name Mangoral) and Oncoral – in clinical development. Ascelia Pharma has global headqu ... Learn more Meet us Ascelia’s employees are passionate and driven to develop products that will help people with rare cancer conditions live longer and healthier lives. Learn more Our values Our values inspire our ambitions, decision making and collaboration to help us reach our highest potential. INTEGRITY We build powerful relationship with mutual respect and adhere to the high ethical standards of our industry COURAGE We work tirelessly and follow our convictions even when it means changing status quo FOCUS We are devoted to i ... Start About us Start About us Career Contact Privacy policy About cookies Pipeline Oncoral Orviglance® IR & Media Subscribe to press releases Press releases & News Financial Reports Contact us Ascelia Pharma AB Hyllie Boulevard 34 215 32 Malmö Sweden Phone: +46 735 17 91 18 info@ascelia.com Follow us Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance® (former working name Mangoral) and Oncoral – in clinical development. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE). © Copyright 2021 - Ascelia Pharma AB | We use cookies to improve our services | Disclaimer Market data could be delayed. Delivered by Modular Finance. We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings". Read our cookie policy Settings Accept all